LCT Presentation at American Diabetes Association
LCT Presentation at American Diabetes
Association
• Confirms DIABECELL®
initial Phase I/IIa trial objectives met
• Concludes
DIABECELL® as potential treatment for unstable Type1
diabetes
28 June 2010: Sydney,
Australia & Auckland, New Zealand. Living Cell
Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global
company pioneering the development of cell implants to treat
diabetes, today announced that its DIABECELL® Phase
I/IIa clinical data was presented at the 70th Scientific
Session of the American Diabetes Association (ADA) on June
27 in Orlando, Florida by Professor Boris Draznin, Director,
Adult Diabetes Program, University of Colorado Denver,
School of Medicine. The ADA annual conference is the
world’s largest and most prestigious diabetes meeting,
attended by over 20,000 members of the professional diabetes
community including physicians, scientists, and other
clinicians and health care professionals.
LCT’s lead product, DIABECELL®, comprises encapsulated neonatal pancreatic islets that are implanted into the abdomen of patients using a simple laparoscopic procedure. Professor Draznin’s presentation on the use of DIABECELL® to treat Type 1 diabetes concluded that it is possible to achieve therapeutic success without immunosuppression. The results of the first trial established proof of concept in humans and safety objectives have been met. DIABECELL® is presently in a dose escalating Phase II clinical trial in New Zealand.
“There is growing acknowledgment by the diabetes medical community globally that DIABECELL® holds great promise in providing an improved treatment for Type 1 diabetes,” said Professor Bob Elliott, LCT Medical Director.
ENDS